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Introduction
Progressive multifocal leukoencephalopathy 
(PML) is a debilitating neurological 
condition caused by the opportunistic 
John Cunningham Virus (JCV). Clinical 
manifestations traditionally develop with 
severely immunosuppressed states. The 
AIDS pandemic led to a preponderance of 
PML diagnoses in patients with CD4 counts 
less than 200/microliter. The advent of 
HAART dramatically improved the morbidity 
and mortality among patients within the last 
decades. However, antiretroviral therapy 
may paradoxically lead to the development 
of PML in the setting of an immune 
reconstitution inflammatory syndrome (PML-
IRIS).1
Traditional diagnosis involved brain 
biopsy, revealing the pathognomonic triad 
of oligodendroglial nuclear inclusions, 
demyelination, and bizarre astrocytes.2 More 
recently, the diagnosis can be made based 
on a constellation of clinical, radiologic, 
and laboratory findings. Clinicians should 
suspect PML in any immunosuppressed 
patient presenting with neurologic signs and 
symptoms. The most efficacious imaging 
modality is an MRI of the brain with and 
without gadolinium; traditional findings 
include hyperintense lesions on T2-weighted 
and FLAIR images, hypointense lesions 
on T1-weighted images, and may include 
gadolinium enhancement.5 Although findings 
typically involve multifocal subcortical white 
matter areas, lesions can also be monofocal 
and involve atypical sites such as the 
cerebellum.3 Cerebrospinal fluid analysis 
(CSF) using a high-sensitivity polymerase 
chain reaction (PCR) assay reveals elevated 
JCV levels.
Risk factors associated with PML-IRIS 
include prior exposure to the JCV, a low CD4 
count, a low HIV load, a higher baseline CD8 
cell count, a history of multiple opportunistic 
infections, and the initiation of antiretroviral 
therapy in close proximity to the onset of 
the opportunistic infection.1 Unfortunately, 
treatment options are limited. However, 
there are few studies demonstrating the 
clinical efficacy of steroids, particularly in 
patients with PML-IRIS.1
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Case
A 66-year-old female immigrant from Kenya with AIDS presented with progressively worsening ataxia. The patient was initially 
diagnosed with AIDS upon discovery of pulmonary tuberculosis in August 2013, for which she completed a nine-month course 
of treatment. She has since been on a fixed-dose combination therapy of Efavirenz, Tenofovir, and Emtricitabine. Her most recent 
CD4 count was 61/microliter, with a viral load of 25 copies/mL. She had developed a wide-based ataxic gait and left-sided deficits 
approximately 10 months after beginning antiretroviral therapy. An MRI of the brain with and without gadolinium revealed a 18mm 
focal area of T2-hyperintensity in the right middle cerebellar peduncle, along with prominent cerebellar leptomeningeal enhancement. 
Cerebrospinal fluid analysis revealed 1400 DNA copies/mL of the JC Virus. The patient’s progressive ataxia, low CD4 count, significant 
JC Virus positivity in the CSF, and MRI findings led to the diagnosis of PML. Because her neurologic symptoms began approximately 10 
months after beginning therapy, a more definite diagnosis of PML-IRIS was made, which can present up to 26 months after beginning 
antiretroviral therapy.1 The patient was promptly begun on high-dose intravenous steroid therapy for symptomatic relief. 
Key Points
•		Clinicians must maintain a high index of suspicion for PML in any immunosuppressed patient presenting with new or worsening 
neurologic signs or symptoms.4
•		Implementation of antiretroviral therapy in AIDS patients does not exclude the possibility of PML.
•		The diagnosis of PML incorporates a constellation of clinical, radiographic, and laboratory data. A pathologic diagnosis is not mandatory.
•		MRI with and without gadolinium is the image of choice, and any focal or nonfocal finding may suggest PML.
•		CSF analysis for the JC Virus is essential in diagnosing PML.













18mm focal area of T2 hyperintensity in the right middle 
cerebellar peduncle with prominent leptomeningeal 
enhancement involving the cerebellum. 
Cerebrospinal Fluid
RBC 16 (Ref: 0/cm)
WBC 88 (Ref: 0-5/cm)
Neutrophils 0 (Ref: 0-6%)
Lymphocytes 96% (Ref: 40-80%)
Monocytes 4% (Ref: 14-45%)
Glucose 57 (Ref: 40-70mg/dL)
Protein 120 (Ref: 15-45mg/dL)
TB Culture Negative
Epstein Barr Virus PCR Negative
Bacterial Culture No growth
Listeria Negative
Cryptococcal Antigen Negative by Latex Agglutination
Cytology No Clonal Proliferation
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